Header Logo

Connection

JORGE CASTILLO to Adult

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Adult.
JORGE CASTILLO
Connection Strength
1.778
Adult
  1. Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
    View in: PubMed
    Score: 0.058
  2. Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.
    View in: PubMed
    Score: 0.057
  3. Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy. Cancer Rep (Hoboken). 2024 Sep; 7(9):e2126.
    View in: PubMed
    Score: 0.055
  4. Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. JCO Glob Oncol. 2022 11; 8:e2200165.
    View in: PubMed
    Score: 0.049
  5. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Rev Anticancer Ther. 2022 05; 22(5):471-478.
    View in: PubMed
    Score: 0.047
  6. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
    View in: PubMed
    Score: 0.042
  7. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378.
    View in: PubMed
    Score: 0.040
  8. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363.
    View in: PubMed
    Score: 0.039
  9. Long survival in patients with Waldenstr?m macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802.
    View in: PubMed
    Score: 0.037
  10. Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.036
  11. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. Br J Haematol. 2019 02; 184(4):650-653.
    View in: PubMed
    Score: 0.035
  12. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and?overall survival. Br J Haematol. 2018 02; 180(3):374-380.
    View in: PubMed
    Score: 0.035
  13. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
    View in: PubMed
    Score: 0.033
  14. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
    View in: PubMed
    Score: 0.033
  15. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr?m macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
    View in: PubMed
    Score: 0.032
  16. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer. 2016 09 01; 122(17):2689-97.
    View in: PubMed
    Score: 0.031
  17. Atrial fibrillation associated with ibrutinib in Waldenstr?m macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3.
    View in: PubMed
    Score: 0.031
  18. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80.
    View in: PubMed
    Score: 0.031
  19. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016 Mar 13; 30(5):787-96.
    View in: PubMed
    Score: 0.031
  20. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6.
    View in: PubMed
    Score: 0.030
  21. Central nervous system involvement by Waldenstr?m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
    View in: PubMed
    Score: 0.030
  22. Rituximab intolerance in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8.
    View in: PubMed
    Score: 0.030
  23. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug; 26(8):1163-72.
    View in: PubMed
    Score: 0.029
  24. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. Leuk Res. 2015 Aug; 39(8):812-7.
    View in: PubMed
    Score: 0.029
  25. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015 May; 169(3):352-5.
    View in: PubMed
    Score: 0.028
  26. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015 Feb 20; 33(6):625-33.
    View in: PubMed
    Score: 0.028
  27. Overall survival and competing risks of death in patients with?Waldenstr?m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9.
    View in: PubMed
    Score: 0.028
  28. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015 Feb 01; 121(3):423-31.
    View in: PubMed
    Score: 0.028
  29. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014 Sep; 38(9):1067-71.
    View in: PubMed
    Score: 0.027
  30. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014 Aug; 89(8):E125-32.
    View in: PubMed
    Score: 0.027
  31. Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always. Am J Hematol. 2014 Aug; 89(8):853-7.
    View in: PubMed
    Score: 0.027
  32. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014 Mar; 89(3):310-4.
    View in: PubMed
    Score: 0.027
  33. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Oct 15; 119(20):3672-9.
    View in: PubMed
    Score: 0.026
  34. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013 Apr; 37(4):386-91.
    View in: PubMed
    Score: 0.025
  35. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Feb 01; 119(3):629-38.
    View in: PubMed
    Score: 0.024
  36. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012 Dec; 53(12):2378-82.
    View in: PubMed
    Score: 0.024
  37. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 01; 118(21):5270-7.
    View in: PubMed
    Score: 0.023
  38. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012 May 24; 119(21):4845-50.
    View in: PubMed
    Score: 0.023
  39. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol. 2012 Mar; 87(3):330-3.
    View in: PubMed
    Score: 0.023
  40. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012 Jul; 36(7):868-75.
    View in: PubMed
    Score: 0.023
  41. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012 Apr; 36(4):413-7.
    View in: PubMed
    Score: 0.023
  42. Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: a unifying diagnosis. Am J Hematol. 2011 Aug; 86(8):690-3.
    View in: PubMed
    Score: 0.022
  43. Plasmablastic lymphoma: a systematic review. ScientificWorldJournal. 2011 Mar 22; 11:687-96.
    View in: PubMed
    Score: 0.022
  44. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol. 2011 Mar; 86(3):256-61.
    View in: PubMed
    Score: 0.022
  45. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010 Nov; 51(11):2047-53.
    View in: PubMed
    Score: 0.021
  46. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010 Oct; 51(10):1822-8.
    View in: PubMed
    Score: 0.021
  47. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010; 15(3):293-9.
    View in: PubMed
    Score: 0.020
  48. Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100(6):980-986.
    View in: PubMed
    Score: 0.014
  49. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.
    View in: PubMed
    Score: 0.012
  50. Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.011
  51. An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2022 02; 63(2):315-325.
    View in: PubMed
    Score: 0.011
  52. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.011
  53. Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021 07; 7:1151-1166.
    View in: PubMed
    Score: 0.011
  54. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leuk Res. 2021 03; 102:106513.
    View in: PubMed
    Score: 0.011
  55. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050.
    View in: PubMed
    Score: 0.011
  56. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019 10; 94(10):1132-1140.
    View in: PubMed
    Score: 0.010
  57. Progression Risk Stratification of Asymptomatic Waldenstr?m Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.010
  58. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
    View in: PubMed
    Score: 0.009
  59. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr?m macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
    View in: PubMed
    Score: 0.009
  60. Profiling of circulating exosomal miRNAs in patients with Waldenstr?m Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
    View in: PubMed
    Score: 0.009
  61. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
    View in: PubMed
    Score: 0.009
  62. Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. Am J Hematol. 2018 09; 93(9):E238-E241.
    View in: PubMed
    Score: 0.009
  63. Multiple myeloma in patients up to 30?years of age: a multicenter retrospective study of 52 cases. Leuk Lymphoma. 2019 02; 60(2):471-476.
    View in: PubMed
    Score: 0.009
  64. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123.
    View in: PubMed
    Score: 0.009
  65. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85.
    View in: PubMed
    Score: 0.009
  66. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018 03; 180(6):831-839.
    View in: PubMed
    Score: 0.009
  67. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? Leuk Lymphoma. 2018 07; 59(7):1753-1755.
    View in: PubMed
    Score: 0.009
  68. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383.
    View in: PubMed
    Score: 0.009
  69. Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
    View in: PubMed
    Score: 0.008
  70. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
    View in: PubMed
    Score: 0.008
  71. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr?m macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
    View in: PubMed
    Score: 0.008
  72. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
    View in: PubMed
    Score: 0.008
  73. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
    View in: PubMed
    Score: 0.008
  74. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016; 57(1):58-62.
    View in: PubMed
    Score: 0.007
  75. Ibrutinib in previously treated Waldenstr?m's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
    View in: PubMed
    Score: 0.007
  76. Extramedullary Waldenstr?m macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
    View in: PubMed
    Score: 0.007
  77. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 09; 124(15):2354-61.
    View in: PubMed
    Score: 0.007
  78. Survival trends in Waldenstr?m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000.
    View in: PubMed
    Score: 0.007
  79. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.007
  80. Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res. 2013 Sep; 37(9):1116-9.
    View in: PubMed
    Score: 0.006
  81. Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literature. Leuk Lymphoma. 2013 Oct; 54(10):2306-9.
    View in: PubMed
    Score: 0.006
  82. EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):512-6.
    View in: PubMed
    Score: 0.006
  83. Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. Leuk Res. 2011 Mar; 35(3):334-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.